Biocon Limited

About company

Established in 1978, Biocon Limited, is India's largest, and Asia's leading, biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. We develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including MAbs, rh-insulin& Insulin Analogs. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG and India's first biologic BioMAb-EGFR; for head and neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, being introduced as Alzumab; for psoriasis in India, in 2013.

  • IN
  • 2015
    On CPhI since
Contact info

Products from Biocon Limited

  • ACTIBLOK AM

    Product ACTIBLOK AM

    Biocon offers a wide range of metabolic which includes actiblok am. Composition: metoprolol succinate 25/50 mg and amlodipine 5 mg tablets. Mechanism of action: metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent, amlodipine: amlodipine is a dihydropyridine calcium channel blocker, which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Indications: uncontrolled hypertension, stable angina and silent ischemic patients
  • ACTIBLOK-IPR

    Product ACTIBLOK-IPR

    Biocon offers a wide range of metabolic which includes actiblok-ipr. Composition: metoprolol extended release 25/50/100mg tablets. Mechanism of action: metoprolol is a beta 1-selective (cardioselective) adrenergic receptor blocking agent. It competitively antagonizes catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output. Indications: hypertension, angina/ihd, myocardial infarction in patients with hypertension, heart failure
  • Advacan

    Product Advacan

    Biocon offers a wide range of nephrology which includes advacan. Composition: each uncoated /coated tablet contains everolimus 0.5mg and 0.25mg. Mechanism of action: everolimus, a proliferation signal inhibitor, prevents allograft rejection in allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated t cells which is driven by t cell-specific interleukins, e.g. Interleukin-2 and interleukin-15. Indications: it is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk, receiving an allogeneic renal or cardiac transplant. Advacan should be used in combination with cyclosporine and corticosteroids

Biocon Limited Resources